DOP2021000176A - 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión - Google Patents

5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Info

Publication number
DOP2021000176A
DOP2021000176A DO2021000176A DO2021000176A DOP2021000176A DO P2021000176 A DOP2021000176 A DO P2021000176A DO 2021000176 A DO2021000176 A DO 2021000176A DO 2021000176 A DO2021000176 A DO 2021000176A DO P2021000176 A DOP2021000176 A DO P2021000176A
Authority
DO
Dominican Republic
Prior art keywords
disorder
dimethyltryptamine
dmt
meo
depression
Prior art date
Application number
DO2021000176A
Other languages
English (en)
Inventor
Terwey Theis
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of DOP2021000176A publication Critical patent/DOP2021000176A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones para su uso en el tratamiento de un paciente que padece un trastorno mental en particular trastorno depresivo mayor, trastorno depresivo persistente, trastorno de ansiedad, trastorno de estrés postraumático, trastorno dismórfico corporal, trastorno obsesivo compulsivo, trastorno alimentario y abuso de sustancias psicoactivas. Se proporcionan además regímenes de dosificación para tratar estos trastornos.
DO2021000176A 2019-02-22 2021-08-20 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión DOP2021000176A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19158774 2019-02-22
PCT/EP2020/054803 WO2020169850A1 (en) 2019-02-22 2020-02-24 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression

Publications (1)

Publication Number Publication Date
DOP2021000176A true DOP2021000176A (es) 2021-11-21

Family

ID=65529503

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000176A DOP2021000176A (es) 2019-02-22 2021-08-20 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión

Country Status (22)

Country Link
US (1) US20220071958A1 (es)
EP (3) EP4349407A2 (es)
JP (1) JP2022521337A (es)
KR (1) KR20210154966A (es)
CN (1) CN114555078A (es)
AU (1) AU2020225410A1 (es)
BR (1) BR112021016153A2 (es)
CA (1) CA3130406A1 (es)
CL (1) CL2021002174A1 (es)
CO (1) CO2021010882A2 (es)
CR (1) CR20210437A (es)
DK (1) DK3927337T3 (es)
DO (1) DOP2021000176A (es)
EA (1) EA202192318A1 (es)
EC (1) ECSP21060868A (es)
FI (1) FI3927337T3 (es)
IL (1) IL285537A (es)
MA (1) MA55021A (es)
MX (1) MX2021009941A (es)
NI (1) NI202100080A (es)
PE (1) PE20220015A1 (es)
WO (1) WO2020169850A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
EP3753923A1 (en) * 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
PL3844147T3 (pl) 2019-11-07 2022-07-18 Small Pharma Ltd Związki chemiczne
EP3868364A1 (en) * 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
BR112023001967A2 (pt) * 2020-08-05 2023-02-28 Univ Basel Método para induzir um estado psicodélico em um indivíduo, método para induzir um estado psicodélico em um indivíduo com segurança, método para fornecer um tratamento psicodélico de curta duração, método para determinar uma dose de dmt para um indivíduo, método para terapia e método para ajustar um estado psicodélico em um indivíduo em tempo real
KR102636385B1 (ko) 2020-08-28 2024-02-14 사이빈 유케이 리미티드 주사용 제제
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
AU2021354006A1 (en) * 2020-10-02 2023-03-02 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
CN112138028A (zh) * 2020-10-10 2020-12-29 南京中医药大学 蟾蜍色胺类物质在制备抗抑郁药物中的应用
WO2022082058A1 (en) * 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
WO2022117640A1 (en) * 2020-12-01 2022-06-09 Small Pharma Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
BR112023022195A2 (pt) 2021-04-26 2024-01-16 Atai Therapeutics Inc Novas composições e métodos de n,n-dimetiltriptamina
WO2022235927A1 (en) * 2021-05-05 2022-11-10 Gilgamesh Pharmaceuticals, Inc. Novel tryptamines and methods of treating mood disorders
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
CA3238583A1 (en) * 2021-11-18 2023-05-25 Cybin Uk Ltd Injectable and inhalable formulations
WO2023186837A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of postnatal depression
WO2023186834A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited Crystalline hydrobromide salt of 5-meo-dmt
WO2023186806A1 (en) 2022-03-27 2023-10-05 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine for the treatment of bipolar disorder
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19803376C1 (de) 1998-01-29 1999-10-14 Markus Storz Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
EP1884254B8 (de) 2006-08-01 2011-02-23 Stobi GmbH & Co. KG Ventilballon für Inhalatoren
CN103816150A (zh) * 2014-03-14 2014-05-28 兰州理工大学 山蚂蝗生物碱单体成分的用途
WO2018195455A1 (en) * 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
WO2019081764A1 (en) * 2017-10-26 2019-05-02 Consejo Superior De Investigaciones Científicas (Csic) ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS

Also Published As

Publication number Publication date
MX2021009941A (es) 2021-12-10
IL285537A (en) 2021-09-30
FI3927337T3 (fi) 2024-05-08
CO2021010882A2 (es) 2022-01-17
CN114555078A (zh) 2022-05-27
EP4353314A2 (en) 2024-04-17
MA55021A (fr) 2021-12-29
KR20210154966A (ko) 2021-12-21
EP3927337B1 (en) 2024-02-14
EP4349407A2 (en) 2024-04-10
CR20210437A (es) 2021-11-02
WO2020169850A1 (en) 2020-08-27
JP2022521337A (ja) 2022-04-06
AU2020225410A1 (en) 2021-08-19
CA3130406A1 (en) 2020-08-27
EP3927337B8 (en) 2024-03-20
EA202192318A1 (ru) 2021-12-21
PE20220015A1 (es) 2022-01-11
NI202100080A (es) 2021-12-06
EP3927337A1 (en) 2021-12-29
BR112021016153A2 (pt) 2021-10-05
DK3927337T3 (da) 2024-04-22
US20220071958A1 (en) 2022-03-10
CL2021002174A1 (es) 2022-01-28
ECSP21060868A (es) 2021-11-30

Similar Documents

Publication Publication Date Title
DOP2021000176A (es) 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para tratamiento de la depresión
CO2021010883A2 (es) Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
CU20120034A7 (es) Compuestos y composiciones como inhibidores de cinasa de proteína
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PE20181088A1 (es) Mecanismo de resistencia a inhibidores de bromodominio bet
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
EA201990602A3 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
CL2022001167A1 (es) Tratamiento de trastornos hepáticos
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
BR112018009476A8 (pt) regime de dosagem de plasminogênio para cicatrização de ferimentos
BR112018015483A2 (pt) formulações farmacêuticas sólidas estáveis que contêm 2-(2-nitro-4-trifluorometil-benzoil)-1,3 -ciclo-hexanodiona
AR116592A1 (es) Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
BR112020014583A8 (pt) Composição para tratar um paciente que sofre de colite ulcerosa e uso da composição como um fármaco